INTERMITTENT VS. CONTINUOUS OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN THE MRC COIN TRIAL IN ADVANCED COLORECTAL CANCER: UPDATED EFFICACY RESULTS, QUALITY OF LIFE AND POTENTIAL PREDICTIVE FACTORS

Detaylı Bibliyografya
Asıl Yazarlar:	Adams, R, Wilson, R, Seymour, M, Meade, A, Madi, A, Cassidy, J, Fisher, D, Kenny, S, Kaplan, R, Maughan, T
Materyal Türü:	Conference item
Baskı/Yayın Bilgisi:	2010

THE IMPACT OF MILD RENAL IMPAIRMENT ON THE TOXICITY OF OXALIPLATIN AND FLUOROPYRIMIDINE REGIMENS: EXPERIENCE IN THE MRC COIN TRIAL
Yazar:: Madi, A, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.
Yazar:: Adams, R, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN)
Yazar:: Adams, R, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

THE ADDITION OF CETUXIMAB TO OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN FIRST-LINE ADVANCED COLORECTAL CANCER IN THE MRC COIN TRIAL: IDENTIFICATION OF POTENTIALLY RESPONSIVE SUBSETS OF PATIENTS
Yazar:: Maughan, T, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Yazar:: Adams, R, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.
Yazar:: Madi, A, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: The MRC COIN trial
Yazar:: Madi, A, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN)
Yazar:: Maughan, T, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Yazar:: Maughan, T, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED COMBINATION CHEMOTHERAPY (CT) IN PATIENTS WITH K-ras WILD-TYPE ADVANCED COLORECTAL CANCER (ACRC): EFFECTS ON OVERALL SURVIVAL. MRC COIN (CR10) TRIAL RESULTS
Yazar:: Adams, R, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

THROMBOCYTOSIS AS A PREDICTIVE AND PROGNOSTIC MARKER IN ADVANCED COLORECTAL CANCER (ACRC): RESULTS OF THE MRC COIN TRIAL EXPLORED
Yazar:: Maughan, T, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Intermittent Chemotherapy (CT) Plus Continuous or Intermittent Cetuximab (C) in the First-line Treatment of Advanced Colorectal Cancer (aCRC): Results of the Two-arm Phase II Randomised MRC COIN-B Trial
Yazar:: Wasan, H, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.
Yazar:: Adams, R, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.
Yazar:: Wood, G, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy
Yazar:: Dae-Won Lee, ve diğerleri
Baskı/Yayın Bilgisi: (2019-05-01)

Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.
Yazar:: Maughan, T, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Chemotherapy choices and doses in frail and elderly patients with advanced colorectal cancer: an MRC randomised clinical trial (FOCUS2)
Yazar:: Seymour, M, ve diğerleri
Baskı/Yayın Bilgisi: (2007)

Efficacy and safety of bevacizumab in combination with oxaliplatin, irinotecan and fluoropyrimidine-based therapy in advanced colorectal cancer
Yazar:: Popov Ivan, ve diğerleri
Baskı/Yayın Bilgisi: (2007-01-01)

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
Yazar:: Seymour, M, ve diğerleri
Baskı/Yayın Bilgisi: (2007)

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
Yazar:: Seymour, M, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
Yazar:: Yeong Hak Bang, ve diğerleri
Baskı/Yayın Bilgisi: (2021-03-01)

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
Yazar:: Iveson, T, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

CETUXIMAB COMBINED WITH INFUSIONAL 5-FLUOROURACIL/FOLINIC ACID AND OXALIPLATIN IN METASTATIC COLORECTAL CANCER: POOLED ANALYSIS OF COIN AND OPUS STUDY DATA
Yazar:: Taieb, J, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy
Yazar:: Madi, A, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Role for nucleotide-excision repair gene variants in oxaliplatin-induced peripheral neuropathy
Yazar:: West, H, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial.
Yazar:: Maughan, T, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Predicting cardiovascular events with fluoropyrimidine chemotherapy using a standard cardiovascular risk calculator
Yazar:: Aderonke Abiodun, ve diğerleri
Baskı/Yayın Bilgisi: (2024-10-01)

Association of pre-existing cardiovascular disease with administration of fluoropyrimidine chemotherapy in patients with gastrointestinal malignancies
Yazar:: Chris Gale, ve diğerleri
Baskı/Yayın Bilgisi: (2024-08-01)

Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer
Yazar:: S Whyte, ve diğerleri
Baskı/Yayın Bilgisi: (2010-10-01)

MRC2020: improvements to Ximdisp and the MRC image-processing programs
Yazar:: J. M. Short, ve diğerleri
Baskı/Yayın Bilgisi: (2023-09-01)

Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. MRC Childhood Leukaemia Working Party.
Yazar:: Harrison, G, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab.
Yazar:: Smith, C, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with -mutated metastatic colorectal cancer: the REVOLUTION study protocol
Yazar:: Antonio Avallone, ve diğerleri
Baskı/Yayın Bilgisi: (2020-08-01)

Results of the use of ramucirumab in combination with irinotecan and fluoropyrimidines in the second-line chemotherapy for disseminated gastric cancer
Yazar:: N. S. Besova, ve diğerleri
Baskı/Yayın Bilgisi: (2019-06-01)

Evolved bacterial resistance against fluoropyrimidines can lower chemotherapy impact in the Caenorhabditis elegans host
Yazar:: Brittany Rosener, ve diğerleri
Baskı/Yayın Bilgisi: (2020-11-01)

Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse events
Yazar:: Theodore J. Wigle, ve diğerleri
Baskı/Yayın Bilgisi: (2021-07-01)

The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection
Yazar:: Young Saing Kim, ve diğerleri
Baskı/Yayın Bilgisi: (2017-01-01)

The puzzling clinical presentation of fluoropyrimidines cardiotoxicity
Yazar:: Linda Cucciniello, ve diğerleri
Baskı/Yayın Bilgisi: (2022-09-01)

Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy
Yazar:: Seid Hamzic, ve diğerleri
Baskı/Yayın Bilgisi: (2020-11-01)

Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece
Yazar:: Georgia Ragia, ve diğerleri
Baskı/Yayın Bilgisi: (2023-09-01)

INTERMITTENT VS. CONTINUOUS OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN THE MRC COIN TRIAL IN ADVANCED COLORECTAL CANCER: UPDATED EFFICACY RESULTS, QUALITY OF LIFE AND POTENTIAL PREDICTIVE FACTORS

Benzer Materyaller

Benzer Materyaller